FOLH1 and posterior cortical atrophy: Owing to the rapid development and advancement of molecular biology [9,10], the emergence of novel molecular biomarkers has provided a new approach for risk stratification and model construction for PCa patients, such as the androgen receptor (AR), prostate-specific membrane antigen (PSMA), and other molecular chaperones [11].